Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
· greenwich lifesciences, inc.
AI Briefing
- Greenwich LifeSciences announces use of GP2 in FLAMINGO-01 clinical trial.
- FLAMINGO-01 is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences.
- Greenwich LifeSciences is a clinical-stage biopharmaceutical company.
Advertisement